Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today […]

Spectral AI Provides Update to Investors

(NASDAQ:MDAI),(NASDAQ:MDAIW), DALLAS, Jan. 22, 2025 (GLOBE NEWSWIRE) — Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView(R) System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced an update on its operating results. Pending the

FlexShopper Appoints Former North Carolina Governor Patrick McCrory to its Board of Directors

(NASDAQ:FPAY), BOCA RATON, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) — FlexShopper Inc. (Nasdaq: FPAY), a leading national lease-to-own (LTO) retailer and payment solutions provider, today announced that it has appointed Patrick McCrory as an independent board member. In addition, FlexShopper announced the retirement of T. Scott King from the Company's Board of Directors effective January

Prostar Announces The Recent Addition Of One Of The Largest Private Construction Management Companies In The United States To Its Growing List Of Enterprise Customers

(TSX-V:MAPS),(Boerse Frankfurt – Freiverkehr:5D00),(OTC US:MAPPF),(Other OTC:MAPPF), GRAND JUNCTION, Colo., Jan. 22, 2025 (GLOBE NEWSWIRE) — ProStar Holdings Inc. (“ProStar(R)” or “the Company”) (TSXV: MAPS) (OTCQX: MAPPF) (FSE: 5D00), a global leader in Precision Mapping Solutions, is proud to announce that one the largest private construction management companies in United States has adopted ProStar's PointMan(R) solution.

Novacap Announces Closing of Its First Fund Dedicated to Digital Infrastructure

MONTRÉAL, Jan. 22, 2025 (GLOBE NEWSWIRE) — Novacap, a leading North American private equity firm, today announced the final closing of the firm's first fund dedicated entirely to investing in digital infrastructure. The Novacap Digital Infrastructure Fund I (the “Fund”) exceeded its target and raised over US$1 Billion from existing and new institutional investors, family

CellFEĀ® Announces Launch of First-in-Class T-Rest™ (“Resting T Cell Kit”) for Breakthrough CAR-T Cell Therapy Manufacturing

CellFE, a leader in non-viral gene editing technology, today announced the launch of its highly anticipated CellFE T-Rest (“Resting T Cell Kit”), a first-in-class cell manufacturing transfection media product designed specifically for resting (quiescent) T cell workflows. The novel T-Rest supports a fully optimized gene editing workflow that utilizes resting T cells as a starting

Spear Education Appoints Dan Butterman as Chief Dental Officer

Experienced Industry Leader Committed to Propeling Dentists and Their Teams to Achieve Great Dentistry Spear Education, the leading provider of advanced dental education and practice management solutions, today announces the appointment of Dan Butterman, DDS, as chief dental officer. Practicing in Centennial, Colorado, since 1994, Butterman brings deep experience and expertise to Spear Education. In

Element Six Unveils Groundbreaking Copper Diamond Composite to Power Advanced Semiconductor Devices

New Copper Diamond Composite Material Provides a Cost-Effective, High-Performance Thermal Management Solution for AI, HPC, and GaN RF Devices Element Six(E6), a pioneer in the development of synthetic diamond advanced material solutions, will launchan innovative Cu-diamond product at Photonics West 2025. Cu-Diamond is a copper plated diamond composite material that has a high thermal and

Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical Trial Landscape

— Lindus Health is the 'anti-CRO' fixing the broken clinical trial industry, setting the stage for greater scientific innovation and lower healthcare costs. — The company offers clinical trials that are up to three times faster and produce demonstrably better quality trial data than traditional players. — The Series B was led by Balderton Capital

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts were accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), taking place January 23-25, 2025, in San Francisco, CA. Details of

Scroll to Top